miR-582-5p serves as an antioncogenic biomarker in intermediate risk AML with normal cytogenetics and could inhibit proliferation and induce apoptosis of leukemia cells.
bioinformatic analysis
gain- and loss-of-function
microRNA profiling
outcome prediction
risk assessment
Journal
Cell biology international
ISSN: 1095-8355
Titre abrégé: Cell Biol Int
Pays: England
ID NLM: 9307129
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
09
12
2019
revised:
05
06
2020
accepted:
13
06
2020
pubmed:
17
6
2020
medline:
11
8
2021
entrez:
17
6
2020
Statut:
ppublish
Résumé
Numerous studies confirmed that aberrant microRNA (miRNA) expression contributes to cancer development and progression. We carried out this study to explore the expression profile of miRNAs in intermediate risk acute myeloid leukemia (AML) and locate certain miRNAs as biomarkers. We profiled differentially expressed miRNAs by performing miRNA sequencing analysis in the patients' samples. Bioinformatic analysis showed the most significantly expressed genes mostly involved in cellular component organization, cell differentiation, and cell development. Reverse-transcription polymerase chain reaction validated the expression of miR-582-5p in different groups of AML samples. It was confirmed that miR-582-5p was downregulated in newly diagnosed AML and relapse/refractory AML compared with CR AML or controls. Among intermediate risk AML patients with normal cytogenetics, a lower level of miR-582-5p is correlated with an unfavorable outcome, and a shorter overall survival. Gain- and loss-of-function experiments revealed that miR-582-5p could inhibit proliferation, suppress migration, and invasion ability and induce apoptosis of leukemia cells. Furthermore, overexpression of miR-582-5p can increase sensitivity of cells to Ara-C. In conclusion, miR-582-5p can serve as an antioncogenic biomarker in intermediate risk AML with normal cytogenetics for risk classification and outcome prediction. These results showed a novel role for miR-582-5p in predicting the prognosis and promoting the tumor growth of AML.
Substances chimiques
Biomarkers, Tumor
0
MIRN582 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2021-2030Subventions
Organisme : Science and Technology Innovation as a Whole Plan Projects of Shaanxi Province
ID : 2014KTCL03-01
Informations de copyright
© 2020 International Federation for Cell Biology.
Références
Acunzo, M., Romano, G., Wernicke, D., & Croce, C. M. (2015). MicroRNA and cancer-A brief overview. Advances in Biological Regulation, 57, 1-9.
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., … Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127, 2391-2405.
Bartel, D. P. (2009). MicroRNAs: Target recognition and regulatory functions. Cell, 136, 215-233.
Bullinger, L., Dohner, K., & Dohner, H. (2017). Genomics of acute myeloid leukemia diagnosis and pathways. Journal of Clinical Oncology, 35, 934-946.
Crisci, S., Amitrano, F., Saggese, M., Muto, T., Sarno, S., Mele, S., … Di Francia, R. (2019). Overview of current targeted anti-cancer drugs for therapy in onco-hematology. Medicina (Kaunas), 55, 414.
Ding, H., Gao, S., Wang, L., Wei, Y., & Zhang, M. (2019). Overexpression of miR-582-5p inhibits the apoptosis of neuronal cells after cerebral ischemic stroke through regulating PAR-1/Rho/Rho axis. Journal of Stroke and Cerebrovascular Diseases, 28, 149-155.
Dohner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Buchner, T., … Bloomfield, C. D. (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an International Expert Panel. Blood, 129, 424-447.
Dohner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Buchner, T., Burnett, A. K., … Bloomfield, C. D. (2010). Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an International Expert Panel, on behalf of the European LeukemiaNet. Blood, 115, 453-474.
Dohner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015). Acute myeloid leukemia. New England Journal of Medicine, 373, 1136-1152.
Estey, E. H. (2018). Acute myeloid leukemia: 2019 update on risk-stratification and management. American Journal of Hematology, 93, 1267-1291.
Greif, P. A., Hartmann, L., Vosberg, S., Stief, S. M., Mattes, R., Hellmann, I., … Spiekermann, K. (2018). Evolution of cytogenetically normal acute myeloid leukemia during therapy and relapse: An exome sequencing study of 50 patients. Clinical Cancer Research, 24, 1716-26.
Hanna, J., Hossain, G. S., & Kocerha, J. (2019). The potential for microRNA therapeutics and clinical research. Frontiers in Genetics, 10, 478.
Hu, N., Chen, L., Wang, C., & Zhao, H. (2019). MALAT1 knockdown inhibits proliferation and enhances cytarabine chemosensitivity by upregulating miR-96 in acute myeloid leukemia cells. Biomedicine & Pharmacotherapy, 112, 108720.
Kamps, R., Brandão, R. D., Bosch, B. J., Paulussen, A. D., Xanthoulea, S., Blok, M. J., & Romano, A. (2017). Next-generation sequencing in oncology: Genetic diagnosis, risk prediction and cancer classification. International Journal of Molecular Sciences, 18, 308.
Li, L., & Ma, L. (2018). Upregulation of miR-582-5p regulates cell proliferation and apoptosis by targeting AKT3 in human endometrial carcinoma. Saudi Journal of Biological Sciences, 25, 965-70.
Mohr, A. M., & Mott, J. L. (2015). Overview of microRNA biology. Seminars in Liver Disease, 35, 3-11.
Shlush, L. I., & Mitchell, A. (2015). AML evolution from preleukemia to leukemia and relapse. Best Practice & Research Clinical Haematology, 28, 81-89.
Uchino, K., Takeshita, F., Takahashi, R. U., Kosaka, N., Fujiwara, K., Naruoka, H., … Ochiya, T. (2013). Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression. Molecular Therapy, 21, 610-619.
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., … Bloomfield, C. D. (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood, 114, 937-951.
Walter, R. B., Othus, M., Burnett, A. K., Lowenberg, B., Kantarjian, H. M., Ossenkoppele, G. J., … Estey, E. H. (2013). Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood, 121, 2424-2431.